PT  - JOURNAL ARTICLE
AU  - Parry, Nicola
ED  - Farnier, Michel
TI  - ODYSSEY FH I and FH II: Alirocumab Significantly Improves Cholesterol Levels in Patients with HeFH
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 18--19
VI  - 14
IP  - 27
4099  - http://mdc.sagepub.com/content/14/27/18.short
4100  - http://mdc.sagepub.com/content/14/27/18.full
AB  - This article presents results from the Efficacy and Safety of Alirocumab SAR236553 (REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy trial [ODYSSEY FH I; NCT01623115] and the Study of Alirocumab (REGN727/ SAR236553) in Patients With HeFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) trial [ODYSSEY FH II; NCT01709500].